ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Nov 30, 2022 09:31 JST
Source:
Eisai
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were published in the New England Journal of Medicine, one of the world's most prestigious peer-reviewed medical journals. For the details of the paper, please refer to: www.nejm.org/doi/full/10.1056/NEJMoa2212948.
The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission. Eisai and Biogen remain committed to disclosing data and information on lecanemab. If approved, we will work to bring the drug expeditiously to people living with early AD and their families.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully gain health authority approval.
For more information, visit www.eisai.com/news/2022/pdf/enews202284pdf.pdf.
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Toyota: Development and Verification of Stationary Storage Battery System Using Electric Vehicle Storage Batteries
May 29, 2023 13:31 JST
Mitsubishi Electric and Mitsubishi Heavy Industries Definitively Agree to Integrate Their Power-generator Systems Businesses
May 29, 2023 11:24 JST
Liquid Hydrogen-Powered Corolla to Participate in the Super Taikyu Fuji 24 Hours Race
May 29, 2023 09:08 JST
Imposing island challenge awaits TOYOTA GAZOO Racing
May 26, 2023 17:35 JST
Results of a Collision Test Conducted on the Driver's Side of a Toyota RAIZE
May 26, 2023 15:07 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26, 2023 14:15 JST
'Fujitsu Technology and Service Vision 2023': sustainability and business converge to solve society's challenges
May 26, 2023 10:12 JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25, 2023 21:02 JST
TOYOTA GAZOO Racing Opens Le Mans 24 Hours Special Website
May 25, 2023 18:28 JST
Hitachi Enhances Diversity, Equity and Inclusion by Supporting LGBTQIA+ Community
May 25, 2023 18:22 JST
Hitachi: Commencement of Joint Studies on Business Initiatives Towards the Development of Sustainable Finance
May 25, 2023 16:10 JST
MHI Thermal Systems to Release Fully Revamped 3HP Model in "HyperInverter" Series of Packaged Air-Conditioners for Domestic Market
May 25, 2023 12:02 JST
SumUp partners with JCB to boost card acceptance for European merchants within its 4-million-strong global network
May 25, 2023 12:00 JST
Mazda 787B to Demonstrate at 24 Hours of Le Mans Centenary Anniversary
May 25, 2023 10:43 JST
Honda to Participate in FIA Formula One World Championship from 2026 Season as Power Unit Supplier for Aston Martin Aramco Cognizant Formula One Team
May 24, 2023 19:01 JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24, 2023 18:03 JST
Mitsubishi Power to Develop Hydrogen-Ready Power Plant for Sembcorp Industries
May 24, 2023 16:06 JST
Mitsubishi Shipbuilding Completes Delivery of Ammonia Fuel Supply System for Large, Low-Speed Two Stroke Marine Engines
May 24, 2023 09:41 JST
More Latest Release >>
Related Release
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
5/26/2023 2:15:00 PM JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
5/25/2023 9:02:00 PM JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
5/24/2023 6:03:00 PM JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
5/20/2023 10:20:00 AM JST
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
5/16/2023 9:27:00 AM JST
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
5/8/2023 11:15:00 AM JST
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
4/6/2023 6:32:00 PM JST
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
4/4/2023 1:23:00 PM JST
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
4/3/2023 1:06:00 PM JST
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
3/31/2023 4:51:00 PM JST
More Press release >>